950160.KQ
Kolon TissueGene, Inc.
1W: +1.6%
1M: +5.7%
3M: +115.1%
YTD: +9.4%
1Y: +248.6%
3Y: +997.6%
₩119,800.00 ($79.63)
+17500.00 (+17.11%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap₩8.51T ($5.7B)
52W Range31250-118900
Volume521,947
Avg Volume525,350
Beta0.13
Dividend—
Analyst Ratings
No analyst coverage
About Kolon TissueGene, Inc.
Kolon TissueGene, Inc. is a biopharmaceutical company, which engages in the development of clinical-stage cell therapies for osteoarthritis. It offers TG-C, a platform technology that consists of a combination of allogeneic primary cells combined with genetically modified cells. The company was founded by Kwan H. Lee on June 9, 1999 and is headquartered in Rockville, MD.
Latest News
No recent news
Recent Insider Trades
No insider trades found